Osteoporosis

OBG Management PubMed

Free CME
Classifieds
Register/Login

November 2008 · Vol. 20, No. 11

UPDATE

OSTEOPOROSIS

Fast Track

Recommend BMD testing for:

women 65 years and older
younger postmenopausal women when the risk-factor profile raises concern
women who have a history of fracture

Postmenopausal women who have osteoporosis and are treated with once-yearly IV zoledronic acid have a higher risk of serious atrial fibrillation than nonusers do

Nononcology patients who are starting an oral or IV bisphosphonate do not require a dental examination beforehand, provided dental care is appropriate and oral hygiene is good

The average duration of alendronate use among patients who had this fracture pattern was 6.9 years, compared with 2.5 years among women who did not

IN THIS ARTICLE

New NOF guidelines
Oral bisphosphonates and atrial fibrillation
Distinctive fracture pattern linked to long-term alendronate
LATE-BREAKING NEWS: DENOSUMAB BUILDS BONE

Steven R. Goldstein, MD

Dr. Goldstein is Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City. He is also Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center.

Subscribe to our e-mail alert. We'll notify you of upcoming articles every month—and send you links to them before they are published.

Changing your e-mail address?

INSTANT POLL
What nonhormonal menopause interventions have you found to be effective?